HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Ocular toxoplasmosis — Clinical Guidelines

Overview

Ocular toxoplasmosis is an inflammatory condition of the retina and choroid caused by Toxoplasma gondii, often presenting as retinochoroiditis in immunocompetent individuals but also affecting immunocompromised patients 1 3.

Diagnosis

Presence of retinochoroiditis lesions

History of toxoplasmosis exposure or acquired infection

Fluorescein angiography may show characteristic lesions

Serological tests (IgM, IgG) to confirm Toxoplasma gondii infection 1 3

Management

First-line treatments:

- Trimethoprim/sulfamethoxazole (for immunocompetent individuals) 1 - Sulfadiazine with pyrimethamine (classical therapy) 1 4

Adjunctive treatments:

- Corticosteroids often used in conjunction with anti-toxoplasmic therapy 1 4

Prophylaxis for frequent relapses:

- Antibiotic prophylaxis preferred in 84.9% of cases 1

Special Populations

Immunocompromised patients: Classical therapy (sulfadiazine/pyrimethamine) preferred 1 4

Pregnancy: Not specifically addressed in provided abstracts

Elderly: No specific considerations noted in abstracts

Comorbidities: Management strategies may vary based on severity and location of lesions 4

Key Recommendations

Treat all active cases of ocular toxoplasmosis, particularly those with visual acuity <20/200, severe vitreous inflammation, or lesions near the fovea or optic disk 1 4 (Evidence: Moderate)

Use trimethoprim/sulfamethoxazole for immunocompetent individuals and sulfadiazine/pyrimethamine for central lesions, immunosuppression, acquired infection, and atypical forms 1 4 (Evidence: Moderate)

Consider antibiotic prophylaxis for patients experiencing frequent relapses 1 (Evidence: Moderate)

Monitor closely for adverse drug reactions, especially gastrointestinal, skin, and neurological symptoms, which are common and can be severe 2 (Evidence: Strong)

References

1 Morais FB, Arantes TEFE, Muccioli C. Current Practices in Ocular Toxoplasmosis: A Survey of Brazilian Uveitis Specialists. Ocular immunology and inflammation 2018. link 2 Guaraldo L, Villar BBF, Durão NMG, Louro VC, Quintana MSB, Curi ALL et al.. Ocular toxoplasmosis: adverse reactions to treatment in a Brazilian cohort. Transactions of the Royal Society of Tropical Medicine and Hygiene 2018. link 3 Holland GN, Lewis KG, O'Connor GR. Ocular toxoplasmosis: a 50th anniversary tribute to the contributions of Helenor Campbell Wilder Foerster. Archives of ophthalmology (Chicago, Ill. : 1960) 2002. link 4 Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. American journal of ophthalmology 2002. link01526-x)

Ocular toxoplasmosis